Top Markets
Coin of the day
Glenmark Life Sciences Limited Glenmark Life Sciences Limited

Glenmark Life Sciences Limited

GLS
株式のランク #7698
Glenmark Life Sciences Limited, an Indian entity established in Mumbai in 2011,... Glenmark Life Sciences Limited, an Indian entity established in Mumbai in 2011, specializes in the creation, manufacturing, and distribution of high-value active pharmaceutical ingredients (APIs). These APIs are utilized across a wide array of chronic therapeutic areas. The company's diverse portfolio includes compounds for managing cardiovascular diseases (e.g., Olmesartan, Rosuvastatin, Amiodarone), central nervous system conditions (such as Oxcarbazepine, Topiramate, Lacosamide), and diabetes (including Glimepiride, Teneligliptin, Linagliptin). Additionally, they produce APIs for pain management (Etoricoxib, Lornoxicam), gastro-intestinal disorders, anti-infective treatments, respiratory ailments, and anti-emetic applications, featuring products like Atovaquone, Fluconazole, and Esomeprazole Magnesium. Beyond API production, Glenmark Life Sciences offers contract development and manufacturing (CDMO) solutions to numerous multinational and specialty pharmaceutical firms. Operating as a subsidiary of Glenmark Pharmaceuticals Limited, the company exports its products worldwide, reaching markets in Europe, North America, Latin America, and Japan.
株価
$12.18
最終同期: 2025-02-17
時価総額
$1.49B
変化(1日)
4.21%
変化(1年)
0.00%
IN
取引 Glenmark Life Sciences Limited (GLS)

カテゴリー

Glenmark Life Sciences Limited(GLS)の利益
2026 時点の利益 TTM: 0
Glenmark Life Sciences Limited の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Glenmark Life Sciences Limited の利益の推移(2026 〜 2026)
各年末の利益
利益 変化
提供された日付のデータは十分ではありません。